Molnupiravir Dosing for COVID-19
Molnupiravir is dosed at 800 mg orally every 12 hours (twice daily) for 5 consecutive days, initiated within 5 days of symptom onset in high-risk outpatients with mild to moderate COVID-19. 12
Specific Dosing Regimen
- Dose: 800 mg (typically four 200 mg capsules, though a single 400 mg tablet formulation is bioequivalent) 3
- Frequency: Every 12 hours (twice daily)
- Duration: 5 days total
- Timing: Must be started within 5 days of COVID-19 symptom onset 12
- Food effect: Can be taken with or without food, as high-fat meals do not meaningfully impact absorption 3
Patient Selection Criteria
This dosing applies specifically to:
- Symptomatic outpatients with confirmed mild to moderate COVID-19
- High-risk patients defined as:
Clinical Context and Caveats
The 2024 American College of Physicians guidelines support considering molnupiravir for this population, though the evidence shows modest clinical benefits 1. Recent meta-analyses demonstrate:
- Mortality reduction: 55-65% relative risk reduction at 28 days, though absolute mortality reduction is only 9 fewer deaths per 10,000 treated 45
- Hospitalization: Benefits vary significantly by age—effectiveness is clearer in the oldest patients (mean age ≥75 years) but questionable in younger high-risk adults (ages 45-74 years) 5
- Vaccinated populations: The PANORAMIC trial found no significant reduction in hospitalization or death among vaccinated adults (adjusted OR 1.06), though there were improvements in symptom duration and quality of life 67
Critical limitation: The drug shows no benefit in hospitalized patients with moderate to severe COVID-19—it is exclusively for early outpatient treatment 48.
Safety Profile
- Adverse events: No difference compared to placebo (RR 1.00) 4
- Serious adverse events: No difference compared to placebo (RR 0.86) 4
- Generally well-tolerated with no dose-limiting toxicities at the 800 mg twice-daily regimen 2
The standard dose of 800 mg twice daily for 5 days should not be adjusted—lower doses have been studied but are not recommended for clinical use 4.